BerGenBio to Present Interim Clinical and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO

Four peer reviewed BerGenBio abstracts on clinical data with bemcentinib accepted for presentation at ASCO
BerGenBio to host KOL reception to showcase bemcentinib studies and potential as a cornerstone of cancer therapy

BERGEN, Norway, 16, May 2018 /PRNewswire/ –…